Murphy & Mullick Capital Management Corp Purchases Shares of 877 Insulet Co. (NASDAQ:PODD)

Murphy & Mullick Capital Management Corp acquired a new position in shares of Insulet Co. (NASDAQ:PODD) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 877 shares of the medical instruments supplier’s stock, valued at approximately $229,000.

Several other large investors have also modified their holdings of the stock. Integrated Wealth Concepts LLC grew its stake in shares of Insulet by 1.7% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier’s stock valued at $596,000 after purchasing an additional 42 shares during the last quarter. Horizon Investments LLC lifted its holdings in shares of Insulet by 3.1% during the fourth quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier’s stock worth $362,000 after purchasing an additional 42 shares during the period. Nisa Investment Advisors LLC grew its position in Insulet by 1.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier’s stock valued at $1,146,000 after buying an additional 43 shares during the last quarter. Glenmede Trust Co. NA increased its stake in Insulet by 2.3% in the 3rd quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier’s stock valued at $484,000 after buying an additional 47 shares during the period. Finally, Graypoint LLC raised its position in Insulet by 5.3% during the 4th quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock worth $243,000 after buying an additional 47 shares during the last quarter.

Insider Buying and Selling at Insulet

In other news, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now directly owns 11,383 shares in the company, valued at approximately $3,187,240. This represents a 52.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.47% of the stock is owned by insiders.

Insulet Stock Down 0.5 %

Shares of NASDAQ:PODD opened at $272.71 on Wednesday. The company has a 50 day moving average of $272.27 and a two-hundred day moving average of $258.19. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $289.46. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The company has a market capitalization of $19.15 billion, a price-to-earnings ratio of 47.10, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. The firm had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. As a group, analysts forecast that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PODD has been the topic of several analyst reports. Piper Sandler lifted their target price on shares of Insulet from $285.00 to $310.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Stifel Nicolaus boosted their target price on Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a research report on Friday, February 21st. StockNews.com cut Insulet from a “buy” rating to a “hold” rating in a report on Tuesday, March 4th. TD Cowen upped their price objective on Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a report on Friday, January 3rd. Finally, Raymond James reissued an “outperform” rating and issued a $328.00 target price (up previously from $294.00) on shares of Insulet in a report on Friday, February 21st. Four analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $292.06.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.